Estimation of mortality risk of very preterm neonates is carried out in clinical and research settings. We aimed at elaborating a prediction tool using machine learning methods. We developed models on a cohort of 23747 neonates <30 weeks gestational age, or <1501 g birth weight, enrolled in the Italian Neonatal Network in 2008–2014 (development set), using 12 easily collected perinatal variables. We used a cohort from 2015–2016 (N = 5810) as a test set. Among several machine learning methods we chose artificial Neural Networks (NN). The resulting predictor was compared with logistic regression models. In the test cohort, NN had a slightly better discrimination than logistic regression (P < 0.002). The differences were greater in subgroups of neonates (at various gestational age or birth weight intervals, singletons). Using a cutoff of death probability of 0.5, logistic regression misclassified 67/5810 neonates (1.2 percent) more than NN. In conclusion our study – the largest published so far – shows that even in this very simplified scenario, using only limited information available up to 5 minutes after birth, a NN approach had a small but significant advantage over current approaches. The software implementing the predictor is made freely available to the community.

In the early phases of the COVID-19 pandemic, repurposing of drugs approved for use in other diseases helped counteract the aggressiveness of the virus. Therefore, the availability of effective and flexible methodologies to speed up and prioritize the repurposing process is fundamental to tackle present and future challenges to worldwide health. This work addresses the problem of drug repurposing through the lens of deep learning for graphs, by designing an architecture that exploits both structural and biological information to propose a reduced set of drugs that may be effective against an unknown disease. Our main contribution is a method to repurpose a drug against multiple proteins, rather than the most common single-drug/single-protein setting. The method leverages graph embeddings to encode the relevant proteins' and drugs' information based on gene ontology data and structural similarities. Finally, we publicly release a comprehensive and unified data repository for graph-based analysis to foster further studies on COVID-19 and drug repurposing. We empirically validate the proposed approach in a general drug repurposing setting, showing that it generalizes better than single protein repurposing schemes. We conclude the manuscript with an exemplified application of our method to the COVID-19 use case. All source code is publicly available.

Whole genome sequencing of bacteria is important to enable strain classification. Using entire genomes as an input to machine learning (ML) models would allow rapid classification of strains while using information from multiple genetic elements. We developed a “bag-of-words” approach to encode, using SentencePiece or k-mer tokenization, entire bacterial genomes and analyze these with ML. Initial model selection identified SentencePiece with 8,000 and 32,000 words as the best approach for genome tokenization. We then classified in Neisseria meningitidis genomes the capsule B group genotype with 99.6% accuracy and the multifactor invasive phenotype with 90.2% accuracy, in an independent test set. Subsequently, in silico knockouts of 2,808 genes confirmed that the ML model predictions aligned with our current understanding of the underlying biology. To our knowledge, this is the first ML method using entire bacterial genomes to classify strains and identify genes considered relevant by the classifier.